City

Atlanta (1)

Durham (1)

Condition

Breast Cancer Triple Negative (3)

Breast Cancer Invasive (1)

Breast Cancer Stage II (1)

Breast Cancer Stage III (1)

Overall Status

Not yet recruiting (2)

Withdrawn (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

Duke University (1)

Emory University (1)

Kasr El Aini Hospital (1)

Collaborator

National Cancer Institute (NCI) (1)

National Comprehensive Cancer Network (1)

Intervention

goserelin (1)

mirvetuximab soravtansine (imgn853) (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Other (3)

Study Type

Interventional (2)

Observational (1)

breast cancer triple negative

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant

Not yet recruiting

Breast Cancer Triple Negative
+3 more

Atlanta, Georgia

Emory University/Winship Cancer Institute

May 18, 2023

Breast Cancer Triple Negative Trial in Durham (Mirvetuximab Soravtansine (IMGN853))

Withdrawn

Breast Cancer Triple Negative

Mirvetuximab Soravtansine (IMGN853)

Durham, North Carolina

Duke University Medical Center

Jul 2, 2018

Breast Cancer Triple Negative Trial (Goserelin)

Not yet recruiting

Breast Cancer Triple Negative

Goserelin

(no location specified)

Feb 18, 2018